Overview
- Australia’s Therapeutic Goods Administration cleared the Wegovy tablet and Foundayo, and the Wegovy pill began appearing on pharmacy shelves on Sunday, giving patients a daily oral option alongside existing injections.
- Regulators in the US, UK and Australia have recently tightened oversight by updating safety labels for rare vision and pancreatitis risks and by imposing stricter online prescribing checks.
- Clinicians report real-world harms when GLP-1s are used without multidisciplinary support, including cases of malnutrition and severe muscle loss such as a patient who lost 10 kilograms of muscle mass.
- Trials and clinical data show stopping GLP-1 treatment typically causes rapid weight regain and reversal of metabolic gains, so doctors urge planning for long-term management with diet, exercise and monitoring.
- Use and sales have surged in recent years—research finds almost a tenfold rise in Australia—and governments are negotiating limited subsidies while many new combination drugs remain in late-stage trials.